National clinical trial on early detection of ovarian cancer available at Massey

NewsGuard 100/100 Score

Virginia Gov. Mark Warner declared September “Gynecological Cancer Awareness Month” in a certificate of recognition to Virginia Commonwealth University’s Massey Cancer Center.

“The governor’s proclamation draws attention to the importance of regular screenings to help women prevent and identify dangerous cancers,” said Weldon Chafe, M.D., a gynecological oncologist and professor of gynecology and obstetrics at VCU. “Gynecological cancers are the fourth-largest cause of cancer deaths among women in the United States, and early detection is the key factor in saving lives.”

More than 80,000 women of all ages and with varying health histories are diagnosed with gynecological cancer each year, including cancers of the ovary, uterus, cervix and vulva.

Cancers that are diagnosed in later stages are often more fatal. For example, the incidence of ovarian cancer is less than one-eighth the incidence rate of breast cancer, yet the fatality rate for ovarian cancer is 70 percent greater.

“Make your appointments at intervals advised by your doctor and keep them,” Chafe said. “These cancers often have few outward symptoms, and pap smears and pelvic exams are key to their early detection.”

Massey Cancer Center also is participating in a national clinical trial on ovarian cancer prevention and early detection. The study, “Prospective Study of Risk-Reducing Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer,” examines possible ways to help certain women lower their risk of ovarian cancer and to find ovarian cancer early. Women who have a strong family history of breast or ovarian cancer, or women who have a change in one of the two genes known to increase the risk of ovarian cancer, BRCA1 and BRCA2, may be eligible.

http://www.vcu.edu/mcc/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New microfluidic device improves the separation of tumor cells and clusters from malignant effusions